ARK Invest Adjusts Biotech Holdings in Latest Trades

The firm increased stakes in several genomic companies while selling shares of Eli Lilly and CareDx.

Updated on Oct. 31, 2026 in Biotech

Isometric editorial illustration of a sculptural DNA double helix structure, representing strategic genomic investment adjustments. — ARK Invest has rebalanced its biotech-focused ETFs, acquiring shares in emerging genomic firms while offloading established pharmaceutical assets like Eli Lilly. AI Illustration. Upload story photo >

Live Poll

Would you adjust your personal investments based on the buying and selling moves of major funds?

ARK Invest recently executed significant trades across its actively managed exchange-traded funds, prioritizing biotech assets over pharmaceutical holdings. The firm increased its positions in firms including Tempus AI and Pacific Biosciences while divesting shares of Eli Lilly and CareDx.

Why it matters

These portfolio reallocations reflect shifting investment priorities within the firm's genomic-focused funds. By rotating capital between specific biotech players, the firm continues to navigate the volatile market landscape of emerging life sciences technologies.

ARK Genomic Revolution and Innovation ETFs acquired a combined 480,274 shares of Pacific Biosciences. Additionally, the firm offloaded 17,626 shares of Eli Lilly and more than 238,000 shares of Bullish.

The players

ARK Invest

This is an investment management firm known for its focus on disruptive innovation and technology-driven sectors.

Eli Lilly

This is a global pharmaceutical company recognized for its extensive research and development in medicine.

Tempus AI

This is a technology company that uses artificial intelligence to analyze clinical and molecular data for healthcare.

Pacific Biosciences

This is a biotech company that provides advanced genetic sequencing solutions for scientific research.

Illumina

This is a leading manufacturer of integrated systems for the analysis of genetic variation and biological function.

The details

The trades occurred during the regular trading session and involved multiple funds managed by the firm. This strategic shift involves balancing new biotech acquisitions against the divestment of established pharmaceutical and financial services stocks.

The trading activity took place on October 30, 2026.

The Tech Race

These transactions follow the established pattern of high-turnover management within the ARK Genomic Revolution ETF portfolio strategy. This activity signals a continued emphasis on high-growth, high-volatility biotech sectors over traditional large-cap pharmaceutical stability.

Retail investors holding shares in the same ETFs may see shifts in their portfolio weighting and overall fund performance. These trades directly alter the underlying asset composition that investors are exposed to within these specific financial products.

The takeaway

Institutional movements in biotech often signal changing market sentiment toward emerging genomic tools. Investors should monitor how these shifts align with their own long-term financial goals and risk tolerance in the technology sector.